Latest News: Treatments & Research

Biogen Community Update on DEVOTE Clinical Trial

20 September 2019 / Posted in: Treatments & Research

Announced publicly at the 13th Congress of the European Paediatric Neurology Society (EPNS), the DEVOTE study will evaluate if higher dosing of nusinersen can provide improved efficacy in the treatment of SMA across a broad population of patients.

Read full story

Physiotherapy - Based Measures (HINE, CHOP INTEND, HMFSE) for People with SMA and how they are used to Monitor Treatment Outcomes

02 September 2019 / Posted in: Treatments & Research

In this new article, our Clinical Care Research Correspondent, Dr Alex Murphy, summarises: the way some of the more commonly used physiotherapy-based outcome measures in SMA work; the research that shows how these measures would be expected to progress for those with SMA who have not accessed drug treatments.

Read full story

Access to Zolgensma Survey and Submission Sent to NICE

08 August 2019 / Posted in: Treatments & Research

Thanks to all who responded to our survey asking for your views on access to Zolgensma for infants with SMA Type 1. We've passed them on to MDUK & TreatSMA and used them in our joint submission with MDUK. Click here to see the results and our submission to NICE.

Read full story

Biogen’s Community Statement Answers Some Questions

07 August 2019 / Posted in: Treatments & Research

SMA UK, MDUK and TreatSMA jointly asked Biogen a number of questions relating to access to the nusinersen Managed Access Agreement with NHS England, and access in the UK in general.

Read full story

Potential SMA Treatment Granted Orphan Medicinal Product Designation By The European Medicines Agency (EMA)

31 July 2019 / Posted in: Treatments & Research

Cytokinetics announced that EMA has granted Orphan Medicinal Product Designation to reldesemtiv for the potential treatment of SMA. Reldesemtiv is a drug that has been shown, in the laboratory, to increase the force generated by skeletal muscle and delay the onset and extent of muscle fatigue.

Read full story

NICE Publishes Final Guidance Following Its Appraisal Of Nusinersen

24 July 2019 / Posted in: Treatments & Research

As there have been no appeals, access to the treatment will be as outlined in the Managed Access Agreement. We have not forgotten those who don't currently have access and will continue to work to change this.

Read full story

Registration for SMA Europe’s 2nd International Scientific & Clinical Congress on SMA Now Open

19 July 2019 / Posted in: Treatments & Research

The conference will be held at Génocentre in Evry, south of Paris between 5th & 7th February 2020 and is open for healthcare professionals and researchers in SMA to attend. The congress will feature a series of talks and workshops covering key scientific and clinical research fields in SMA.

Read full story

Response from NICE to the SMA Community re: NICE's Communications About Access to Nusinersen

10 July 2019 / Posted in: Treatments & Research

We have received this reply in response to the letter sent by SMA UK, MDUK and TreatSMA on 14th June 2019.

Read full story

NICE / NHS England announce changes to the nusinersen Managed Access Agreement

03 July 2019 / Posted in: Treatments & Research

The MAA for nusinersen (Spinraza) will now include paediatric patients who have recently (in the previous 12 months) lost the ability to walk independently. It also commits to considering any significant evidence being made available by Biogen in relation to all with SMA Type 3 who are non-ambulant, that may impact on the eligibility criteria of the MAA. These are just two changes following many confidential discussions which we have been unable to report on until now.

Read full story

Scottish Government Updates On Access To Nusinersen For Those With SMA Types 2 And 3

02 July 2019 / Posted in: Treatments & Research

Following recent communication from the Scottish Government, the Scottish Medicines Consortium webpage for nusinersen has been updated to advise that, as well as being available for those with SMA Type 1, from July 2019 nusinersen can be prescribed for those with SMA Types 2 and 3.

Read full story